GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.27
-0.28 (-0.41%)
As of 2:51PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close68.55
Open68.52
Bid68.55 x 1800
Ask68.56 x 1400
Day's Range67.82 - 69.51
52 Week Range60.32 - 89.54
Volume4,548,748
Avg. Volume7,957,717
Market Cap88.315B
Beta (3Y Monthly)1.34
PE Ratio (TTM)56.66
EPS (TTM)1.21
Earnings DateFeb 4, 2019
Forward Dividend & Yield2.28 (3.37%)
Ex-Dividend Date2018-12-13
1y Target Est84.58
Trade prices are not sourced from all markets
  • 3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss
    Motley Fool7 hours ago

    3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss

    Results from a few clinical trials reading out in 2019 could make it a year to remember.

  • Business Wire23 hours ago

    Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019

    Gilead Sciences, Inc. (GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and provide a business update.

  • Better Buy: Biogen vs. Gilead Sciences
    Motley Fool4 days ago

    Better Buy: Biogen vs. Gilead Sciences

    Which stock wins in a battle between these two big biotechs?

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    # Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $7.20 billion over the last one-month into ETFs that hold GILD are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts
    Investor's Business Daily5 days ago

    These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts

    Biotech stocks Gilead Sciences, Biogen and Celgene are set to beat some aspects of Q4 earnings estimates, an analyst predicted, saying he expects conservative guidance.

  • Benzinga5 days ago

    Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year

    Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation of fat in the liver of people who do not consume alcohol. NAFLD is a less serious condition, although non-alcoholic steatohepatitis, or NASH — a subset of NAFLD — is life-threatening, given its potential to cause liver scarring and cirrhosis. NAFLD affects about 80-100 million people in the U.S. alone — roughly 25 percent of the total population.

  • Why Gilead Sciences Stock Sank by 12.7% in 2018
    Motley Fool6 days ago

    Why Gilead Sciences Stock Sank by 12.7% in 2018

    Gilead's stock churned lower yet again last year, but the biotech could finally be nearing an inflection point.

  • Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon
    Zacks6 days ago

    Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

    Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    # Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $9.02 billion over the last one-month into ETFs that hold GILD are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Will Dividend Stocks be the Hot Stocks of 2019?
    Zacks7 days ago

    Will Dividend Stocks be the Hot Stocks of 2019?

    With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.

  • Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
    Zacks8 days ago

    Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

    Gilead Sciences (GILD) closed at $68.52 in the latest trading session, marking a +1.89% move from the prior day.

  • Here's How The Government Shutdown Will Affect These Medical Stocks
    Investor's Business Daily8 days ago

    Here's How The Government Shutdown Will Affect These Medical Stocks

    The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.

  • Here's Why Verastem Tumbled 34.1% in December
    Motley Fool12 days ago

    Here's Why Verastem Tumbled 34.1% in December

    Investors have been worried about a difficult new drug launch.

  • NASH Space in Focus in 2019 as Firms Look to Diversify
    Zacks12 days ago

    NASH Space in Focus in 2019 as Firms Look to Diversify

    NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

  • Have Insiders Been Selling Gilead Sciences, Inc. (NASDAQ:GILD) Shares?
    Simply Wall St.14 days ago

    Have Insiders Been Selling Gilead Sciences, Inc. (NASDAQ:GILD) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Value Added: 7 Top Stocks for 2019
    Kiplinger14 days ago

    Value Added: 7 Top Stocks for 2019

    Making money in the stock market this year is going to take all the skill and luck you can muster. The global economy is slowing, a trade war with China still lingers despite negotiations, and the Federal Reserve remains likely to raise short-term interest rates, albeit slowly. But you still can find promising investments. To identify some of the top stocks right now, I interviewed Jerome Dodson, manager of Parnassus Endeavor Fund (PARWX) and founder of the Parnassus funds. Based in San Francisco, Parnassus is the largest U.S. fund firm focused on buying good stocks that are also, in the firm's view, good corporate citizens in terms of the environment, social and corporate governance issues. More to the point, Dodson's fund has a first-class record. Endeavor returned an annualized 16.3% over the past 10 years - an average of 3.1 percentage points per year better than the Standard & Poor's 500-stock index. Dodson, 75, is a contrarian investor who loves to pounce on stocks that have been pummeled. Given the selloff, this is precisely Dodson's kind of market. Read on for his seven top stocks for 2019. ### SEE ALSO: 19 Best Retirement Stocks to Buy in 2019

  • Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
    Zacks14 days ago

    Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

    It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

  • Cell therapy pioneer eyes Bay Area manufacturing
    American City Business Journals14 days ago

    Cell therapy pioneer eyes Bay Area manufacturing

    The South San Francisco company, which has quickly grown to 105 employees and raised more than a half-billion dollars, plans to site a cell manufacturing facility in the Bay Area.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    # Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding GILD are favorable, with net inflows of $20.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • The 9 Best Stocks of America’s Last Bear Market
    Kiplinger15 days ago

    The 9 Best Stocks of America’s Last Bear Market

    It's official. The Nasdaq Composite has waded all the way into bear-market territory, now down 20% from its late-September peak. The Dow Jones Industrial Average and the Standard & Poor's 500-stock index aren't far behind. Whether the fourth-quarter selloff is merited doesn't entirely matter. If the crowd believes the rout suffered over the course of the past three months is the shape of things to come, stocks will lose more ground as investors create the very bear market they fear. It's a self-fulfilling prophecy. But here at the precipice of seeing the market's condition shift from bad to worse, remember: Not all stocks have to lose ground, even if the tide is going out. One only has to look at the nine big stocks that managed to gain ground between October 2007 and March 2009 - America's last bear market - to appreciate that some companies have staying power even in rough environments. Here are nine S&P; 500 stocks that actually gained in the face of the 2007-09 bear market. Notice in all nine cases, there was something unique about these organizations that shielded them from the full impact of economic woe. And in some cases, they still look properly positioned to fight off another bear attack. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Investing.com15 days ago

    Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close

    Investing.com - Union Pacific , Motorcar Parts of America and Nektar Therapeutics surged on Tuesday, underpinning a second-straight day of gains in the broader market.

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    # Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding GILD are favorable, with net inflows of $20.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 7 Things to Expect for Gilead Sciences in 2019
    Motley Fool15 days ago

    7 Things to Expect for Gilead Sciences in 2019

    The big biotech's executives spill the beans on plans for the new year at the J.P. Morgan Healthcare Conference.

  • Business Wire16 days ago

    Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)

    Gilead Sciences, Inc. (GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults with chronic hepatitis C virus (HCV) infection with decompensated cirrhosis, and for patients with chronic HCV infection without cirrhosis or with compensated cirrhosis who have had prior treatment with a direct-acting antiviral therapy (DAA).